Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
about
B cells with regulatory properties in transplantation toleranceDesensitization for solid organ and hematopoietic stem cell transplantationLate and chronic antibody-mediated rejection: main barrier to long term graft survivalTreatment options and strategies for antibody mediated rejection after renal transplantationUnraveling the Role of Allo-Antibodies and Transplant InjuryBortezomib in kidney transplant recipients with antibody mediated rejection: three case reportsBortezomib use in a pediatric cardiac transplant center.Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trialUse of bortezomib as anti-humoral therapy in kidney transplantation.Current status of xenotransplantation and prospects for clinical applicationProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsThe generation and maintenance of serum alloantibody.B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.Bortezomib in kidney transplantation.Recent advances in renal transplantation: antibody-mediated rejection takes center stageAntibody-mediated rejection: an evolving entity in heart transplantation.Antibody-mediated rejection in kidney transplantation: a reviewTolerance and lymphoid organ structure and function.Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients.Adult Living Donor Liver Transplantation Across ABO-Incompatibility.Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney TransplantationHuman leukocyte antigen antibody incompatible renal transplantationMinimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.Detecting adaptive immunity: applications in transplantation monitoring.Barriers to successful transplantation of the sensitized patient.Kidney disease associated with plasma cell dyscrasiasAntibody-mediated rejection in kidney transplantation: an update.Current approaches to the management of highly sensitized kidney transplant patients.Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch?New therapeutic approaches to antibody-mediated rejection in renal transplantation.Proteasome inhibitor therapy for antibody-mediated rejection.Clinical and investigational use of proteasome inhibitors for transplant rejection.Emerging drugs for the treatment of transplant rejection.Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.Cardiac antibody-mediated rejection.Prevention of antibody-mediated kidney transplant rejection.Transplant immunology for non-immunologist.
P2860
Q26771404-D6938138-3E26-44BC-BC93-A5C2FF8800CBQ26863564-E58E5BF6-C412-415B-86DB-DD9A1EA0EA33Q27006030-8114483A-3FD9-443C-BA9E-50DBAEA031A0Q27021397-0FFDC557-29A6-4279-B032-B159D5A183BCQ28069336-0858AA5A-B919-4C35-B58C-C9AFD19EC1B1Q33389918-8EB3F969-DC6C-4AE8-9AC0-788061552287Q33415926-AB09A6B4-8C79-4C86-A701-7DC645D19207Q33437712-AD4BEA25-AC7B-4292-8328-B9F6D9060D95Q33438199-08B18146-C237-4C11-BEDE-633C09A72D50Q33584895-7FA7CC86-BA06-4503-83E7-5F98CD616383Q33627580-60BFE811-1486-4BB6-A53F-07B991CA66B3Q33835678-169CF52A-F2A9-4BE0-B7E1-44BD51583C39Q34085747-ECBEC272-7052-4950-A5E5-CF59D37FB140Q34106158-59BD0BED-04D1-420C-B19A-C22C4E64226AQ34159016-5B2E3782-A885-4BB2-B999-A94CA12FED4EQ34189435-52A56F58-E4C1-4738-BC16-151031E5F7B7Q35659332-BF0472BD-E7DA-431C-A5F1-46A0FEF15260Q35876250-37F725F4-20D5-4E68-9565-5AF64470FA64Q35915453-3C64B6B6-F170-4CF8-8125-CC497CA63412Q35927529-4CA04206-9B68-4DAD-9230-069B8BCD5772Q36176992-E79C7D9A-C20A-4A76-BF7F-1BEFB873BC5DQ36206934-CD79C0F1-7889-409E-AC4C-6273BBF15D0BQ36566858-2FB1213C-6755-48D1-BD49-868E4A065A8EQ36612789-04976E1B-3440-441E-BEBF-E5E81FD733EEQ37361071-5DF2CCA2-49E3-4DD1-9232-2932C3B5F693Q37665145-D0880126-5208-48C2-B234-FCE759AED153Q37685073-BE5E2001-DAD8-4DEE-9469-541E9E4358EDQ37742103-085E6574-EDFB-4C42-ADBB-B2781037979FQ37750106-4273D12E-9EAA-4DB5-AE69-7BFA8D1B6447Q37835834-07D240D3-004D-4747-B28E-AA4591FB30B2Q37836967-21AF2E43-4399-4583-BDCD-DA0EFCC1C6D0Q37854488-C8DEB69B-3313-49F7-B44E-E68C4026B58EQ37898509-E60E03E4-FD01-47C8-9615-383F21B927E6Q37925104-14DA690B-93E1-45E8-A7C2-7C7BBAEC3869Q37931981-59DD3069-1653-49D8-A77D-E7349F014B92Q37960177-890124F4-639D-4CB7-A08D-CE00FFD0295EQ37990988-5D7C9B16-73C0-4546-8207-60F1EBDFC725Q38002449-F4E5DA2E-5154-49B5-830F-BB383F766604Q38010231-5893F9DE-CD83-4551-96A3-85D0B54C87A9Q38017160-A7710C15-650E-4848-A7CE-9C057888890B
P2860
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Proteasome inhibition causes a ...... nting alloantibody production.
@en
Proteasome inhibition causes a ...... nting alloantibody production.
@nl
type
label
Proteasome inhibition causes a ...... nting alloantibody production.
@en
Proteasome inhibition causes a ...... nting alloantibody production.
@nl
prefLabel
Proteasome inhibition causes a ...... nting alloantibody production.
@en
Proteasome inhibition causes a ...... nting alloantibody production.
@nl
P2093
P1476
Proteasome inhibition causes a ...... nting alloantibody production.
@en
P2093
H S Pollinger
M D Stegall
P304
P356
10.1111/J.1600-6143.2008.02461.X
P407
P577
2008-10-31T00:00:00Z